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Abstract
Background: Sickle cell disease (SCD) has extremely variable phenotypes, and several factors have been
associated with the severity of the disease. Objectives: To analyze the chronic complications of SCD and
look for predictive risk factors for increased severity and number of complications. Methods:
Retrospective study including all children followed for SCD in the Paediatric Haematology Unit of a tertiary
hospital in Portugal, who completed 17 yr old between the years 2004 and 2013. Results: We identified
44 patients, 55% female and 98% black. Chronic complications occurred in 80% of cases. Slight dilatation
of the left ventricle was the most frequent complication (47.7%), followed by respiratory function disturbs
(43.2%), microlithiasis or cholelithiasis (40.9%), increased flow velocity of cerebral arteries (31.8%),
enuresis, delayed puberty and bone abnormalities (6.8% each), sickle cell retinopathy and leg ulcer (4.6%
each) and recurrent priapism (2.3%). We identified a statistically significant association between
leukocytes >15 000/lL and a higher number of hospitalizations (P < 0.001) and chronic complications of
the disease (P = 0.035). The occurrence of dactylitis in first year of life was also significantly associated
with a higher number of hospitalizations (P = 0.004) and chronic complications (P = 0.018). The presence
of a-thalassemia was associated with a lower number of chronic complications (P = 0.036). Conclusions:
Leucocytosis and dactylitis in the first year of life can be predictors of SCD severity, while the presence of
a-thalassemia can be protective. The determination of early predictors of chronic complications of SCD
may improve the comprehensive care of these patients.
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Sickle cell disease (SCD) is a chronic anemia characterized
by a homozygote mutation in the b-hemoglobin gene. The
prevalence of SCD in Europe is about 15 cases per 100 000
inhabitants (1).
Sickle cell disease has extremely variable phenotypes. Some
patients have a mild disease that can be clinically unappar-
ent, while others can be affected by most of its severe com-
plications (2). Therefore, understanding the relationship
between clinical and laboratory parameters of SCD may be
useful in predicting the severity of disease and the risk of
early death (2). This would not only allow a risk-based
counseling for families but also justify the early use of dis-
ease-modifying or curative interventions, such as hydroxy-
urea, chronic transfusions, or stem-cell transplantation (3).
Various factors have been found to modulate sickle cell dis-
ease (4). A low level of fetal hemoglobin (HbF) (4, 5), a low
level of total hemoglobin (5, 6), and an increased base-line
white-cell count (2, 6) above 15 000/mm3 were associated
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with disease severity and increased risk of death (5). The rec-
ommended level of HbF in these patients is not consensual in
the literature (4). However, levels of HbF above 5.4% have
been associated with a risk reduction in early onset of dactyli-
tis, pain crises, acute chest syndrome, and acute splenic
sequestration, while levels above 10% were associated with
fewer chronic leg ulcers in children (4). Clinical severity of
disease is also influenced by the presence of a-thalassemia (2,
4) and by the haplotype linked to the b-globin gene (4). On
the other hand, some authors have demonstrated that children
who experienced dactylitis in the first year of life are more
likely to have adverse outcomes in later childhood (3, 6, 7).
The purpose of this study was (i) to characterize the
chronic complications of SCD in our patients and (ii) to ana-
lyze the association between the presence of previously
described severity risk factors and the number of hospitaliza-
tions and chronic complications.
Materials and methods
A retrospective study was performed including all children
followed in the Unit of Paediatric Haematology of Hospital
de Santa Maria (UHP–HSM) for SCD, who completed 17 yr
between the years 2004 and 2013. Clinical data were col-
lected from patients’ clinical notes. SCD diagnosis was
established through hemoglobin electrophoresis in all
patients, associated to isoelectric focusing of the hemoglobin
technique or cation-exchange high-performance liquid chro-
matography. The steady-state leukocyte count and hemoglo-
bin level were calculated through the mean of three values
obtained after the first year of life, in the absence of acute
illness. The value of HbF level used in this series was the
first obtained after the first year of life, (determined with
Betke’s method). Alpha-thalassemia was diagnosed through
polymerase chain reaction (PCR) detection of -a3.7 and
-a4.2 deletions in the genes encoding alpha globin chain.
These mutations correspond to more than 95% of a-thalasse-
mia cases in the Portuguese population. Cardiac ejection
fraction was considered reduced when inferior to 55%.
Obstructive lung defect was defined as a forced expiratory
volume in the first second (FEV1)/forced vital capacity
(FVC) <80% and a FEV1 <80%. Restrictive defect was
defined as FVC <80% with normal or increased FEV1/FVC.
Statistical analysis was performed by IBMSPSS version
21 software. Correlation between variables in scale measure
was studied by Pearson correlation coefficient. Mann–Whit-
ney U-test and median test were applied to look for differ-
ences in the average between two independent groups. A
P-value of <0.05 was defined as statistically significant.
Results
We identified 44 patients, followed in the UHP-HSM for
SCD, who completed 17 yr old in the last 10 yr. Twenty-four
(55%) were female and 20 (45%) were male. Forty three
(98%) were African descendants and 1 (2%) was Caucasian.
The median age at diagnosis was 10 months (min: 3 d, max:
12 yr and 5 months). Patients’ hematological laboratory data
are summarized in Table 1.
Beta-hemoglobin S haplotypes were characterized in 29
patients (66%). The most common haplotype was Bantu/
Bantu in 16 cases, followed by Bantu/Benim in five cases
and other less frequent haplotypes (Benim/Benim in three
cases, Senegal/Senegal in two and Bantu/Senegal, Bantu/
Black two and Bebim/Senegal in one case each).
Alpha-thalassemia was present in 18 cases (41%), caused
by -a3.7 deletions in two alpha genes in 16 cases and in one
alpha gene in seven cases.
The median number of hospital admissions during the fol-
low-up period was 7. Five patients (11%) had no admis-
sions, while nine patients (20%) had 20–30 hospitalizations.
The most frequent cause of admission was painful crisis
(54%), followed by infection (34%), splenic sequestration
and acute chest syndrome (3% each), and less commonly
aplastic crisis and leg ulcer (1.5% each). Four patients (9%)
had dactylitis before their first birthday.
Chronic complications of SCD occurred in 35 patients
(80%), with a median of two complications per patient
(Table 2). Of the 21 patients with slight dilation of left ven-
tricle, seven presented a reduced ejection fraction, ranging
from 30% to 49%. No diastolic dysfunction was found. Of
the 19 patients with respiratory function abnormalities, 15
had a restrictive defect, two had an obstructive defect, and
two had both conditions. Six of the 18 patients with micro-
lithiasis developed gallstones and were submitted to chole-
cystectomy during childhood. One of the 14 patients with
increased flow velocity of cerebral arteries had a time-aver-
aged mean of maximum velocity (TAMMV) higher than
200 cm/s, presenting a high risk of stroke. This patient and
the one with recurrent priapism and persistent leg ulcer were
submitted to transfusion therapy. Two other patients were
treated with hydroxyurea, one due to recurrent episodes of
acute chest syndrome and the other due to more than three
admissions for painful crisis per year. There were no cases
of renal dysfunction, stroke, or death in this series.
Table 1 Patients’ hematological laboratory data
Hematological
values Mean Minimum Maximum
Steady-state
Hemoglobin
level
8.0  0.9 g/dL 5.9 g/dL 9.7 g/dL
Fetal
Hemoglobin
6.8  4.8% 0.8% 9.7%
Leukocyte
count
12.95 9
103/mm3
6.6 9 103/mm3 21.9 9 103/mm3
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Leukocyte count above 15 000 9 103/mm3 was found in
11 patients (25%) and was significantly associated with a
higher median number of admissions (20 vs. 5, Mann–Whit-
ney P < 0.001) and chronic complications of the disease (3
vs. 1, Mann–Whitney P = 0.035) (Fig. 1).
The steady-state basal hemoglobin was under 7 g/dL in 4
patients (9.1%) and above 7 g/dL in 40 patients (90.9%).
There was not a significant difference between these two
groups regarding the median number of admissions (13.5 vs.
6, Mann–Whitney P = 0.512), admissions for painful crisis
(3 vs. 2, P = 0.917), or chronic complications of disease (2
vs. 2, Mann–Whitney P = 0.767).
The percentage of HbF as a continuous covariate was not
significantly related to the total number of hospital admis-
sions (rpearson = 0.277 P = 0.069) (Fig. 2), to the number
of admissions for painful crisis (rpearson = 0.242
P = 0.113), or to the number of chronic complications
(rpearson = 0.258 P = 0.091).
The four patients who had dactylitis before their first
birthday presented a significant higher median number of
hospital admissions (23 vs. 6, Mann–Whitney P = 0.004)
and chronic complications (3 vs. 1.5, Mann–Whitney
P = 0.018) (Fig. 3).
Patients with a-thalassemia presented a significantly lower
median number of chronic complications comparing with
patients without thalassemia (1 vs. 3, median test P = 0.036)
(Fig. 4) as well as a lower median number of hospital
admissions (5 vs. 7.5, Mann–Whitney P = 0.811).
Discussion
Sickle cell disease is a genetic disorder causing anemia and
acute and chronic tissue damage in multiple organs. The sur-
vival of patients with SCD has steadily improved with the
(i) institution of immunizations, prophylactic antibiotics, and
Table 2 Prevalence of chronic complications of SCD
Chronic complications
Number of
affected
patients (%)
Slight dilatation of left ventricle 21 (47.7)
Respiratory function abnormalities 19 (43.2)
Microlithiasis/cholelithiasis 18 (40.9)
Increased flow velocity of cerebral arteries 14 (31.8)
Enuresis 3 (6.8)
Delayed puberty 3 (6.8)
Bone abnormalities 3 (6.8)
Proliferative retinopathy 2 (4.6)
Leg ulcer 2 (4.6)
Recurrent priapism 1 (2.3)
Figure 1 Association between leukocyte count and the number of
chronic complications.
Figure 2 Distribution of the total number of admissions in function of
HbF.
Figure 3 Association between the occurrence of dactylitis before the
first year of life and the number of chronic complications.
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hydroxyurea; (ii) earlier diagnosis and treatment of disease
complications; and (iii) improvement in patient education
and comprehensive care (4, 8). Therefore, the disease has
shifted from a fatal pediatric illness to a chronic condition
associated with progressive deterioration of the organ func-
tion and quality of life (4, 8). In our study, most patients
presented one or more chronic complications and no one
died. These results reveal the tendency of the disease to a
chronic multiorganic dysfunction and reinforce the need of
periodic screening tests for possible complications as well as
multidisciplinary approach of these patients through their
life.
Cardiac exams findings are rarely normal in SCD (9). The
heart is usually enlarged, and hyperactive precordium and
systolic murmurs are found in most patients (9). This is well
illustrated in our study, as almost half of the children
(47.7%) presented a slight dilatation of left ventricle. Evalua-
tion of the pulmonary status in patients with SCD may
reveal a variety of chronic manifestations including restric-
tive and obstructive lung disease, hypoxemia, and pulmonary
hypertension, which may present separately or combined (8).
Airway hyperreactivity occurs in nearly two-thirds of chil-
dren with SCD (8). We found respiratory function abnormal-
ities in 43.2% of patients, most of them (79%) presenting a
restrictive lung disease. Ultrasound surveys of patient popu-
lations indicate that the onset of cholelithiasis occurs as early
as 2–4 yr old, and its prevalence progressively increases
with age, affecting nearly 30% of patients until 18 yr old
(9). Microlithiasis was frequent in our patients (40.9%) but
only one-third of them developed cholelithiasis. Ischemic
stroke can occur in at least 11% of patients with SCD by
the age of 20 yr old (10). High risk is associated with distal
intracranial internal carotid (ICA) and proximal middle
cerebral artery (MCA) stenosis which can be detected by
transcranial doppler (10). This procedure is recommended
for routine screening for stroke risk in children with SCD
(11). The risk of stroke in children with high flow velocity
in the ICA and MCA can be reduced with regular red cell
transfusion, whose goal is to maintain hemoglobin S below
30% (10). An increased flow velocity of intracranial arteries
was present in almost one-third of patients (32%) but there
were no cases of stroke. Other chronic complications as
renal dysfunction, leg ulcer,and proliferative retinopathy (9,
12, 13) are typically associated with an older age, which
may explain the lower incidence of these complications in
our series.
The patients with more symptomatic disease have a higher
risk of early death, and the high frequency of acute painful
episodes is a measure of clinical severity associated with a
poor prognosis (2, 5, 14). Therefore, we considered the
number of admissions and chronic complications as markers
of SCD’s severity.
Although the role of leukocytes in the pathogenesis of
SCD remains not completely clarified, leukocytes are known
to be involved in the process of arterial occlusion and may
be associated with the severity of the disease (6, 15). This is
consistent with our results as we found a significant associa-
tion between leukocyte count above 15 000 9 103/mm3 and
a higher number of hospitalizations and chronic complica-
tions of the disease.
In our report, the patients who had dactylitis in their first
year of life presented a significant higher number of admis-
sions and chronic complications comparing with the patients
with no dactylitis in that period. This result reinforces the
early onset of dactylitis as a predictive factor of disease
severity.
The different beta-hemoglobin haplotypes have varying
degrees of severity (4). Senegal haplotype has the least
severe course of disease, probably due to the association
with high levels of HbF, while Bantu haplotype presents the
lowest HbF levels and is related to a more severe disease
(4). As we have a small sample of each haplotype, it was
not possible to study the statistical association between the
haplotypes and the number of complications or admissions
in our patients.
The presence of a-thalassemia is associated with a lower
intraerythrocytic hemoglobin S concentration within the
microcytic red blood cells, which reduces polymerization of
deoxyhemoglobin S and hemolysis. In our series, the pres-
ence of a-thalassemia was significantly associated with a
lower number of chronic complications. It was also associ-
ated with a lower number of hospital admissions, although
with no statistical significance.
HbF level was described as the most straightforward labo-
ratory risk factor for severe SCD (5). Several studies demon-
strated that a higher level of HbF predicts a minor severity
of the disease (4, 5, 14) and that even moderate increases in
the HbF level could reduce the pain rate (14). In our study,
the percentage of HbF was not significantly related to the
Figure 4 Association between the presence of a-thalassemia and the
number of chronic complications.
4 © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Predictive factores of severity in SCD Silva et al.
number of hospitalizations, admissions for painful crisis or
number of chronic complications, contrary to what we
expected. However, as we obtained a borderline P-value,
these results are probably related to the small dimension of
the sample, which is a limitation of our study.
The role of low hemoglobin level in the different compli-
cations of SCD can vary. A low hemoglobin level has previ-
ously been correlated with an increased risk of stroke and
death in childhood (5, 6, 15). On the other hand, higher
hemoglobin levels correlate with increased risks of acute
chest syndrome and painful crisis (6, 14, 15). In our study,
there was not a significant association between hemoglobin
level and the number of total admissions, admissions for
painful crisis or chronic complications of SCD.
Hydroxyurea is an antineoplastic agent that inhibits ribo-
nucleotide reductase, increasing HbF within red blood cells
(16). A double-blinded multicenter prospective pediatric trial
about the use of hydroxyurea in very young children
revealed its association with a significant (i) reduction in
pain, dactylitis, acute chest syndrome, and need of hospital-
ization and transfusion and (ii) improvement in laboratory
parameters (higher Hb and HbF and lower neutrophils
count), with relative lack of toxicity (16). As hydroxyurea
seems to be associated with a better quality of life and prob-
ably with a better long-term prognosis, it should be consid-
ered in the treatment of early age children with SCD, even
in the absence of clinical symptoms (16).
Sickle cell disease is a chronic disease associated with a
progressive deterioration in multiple organ function. This
fact explains the need of periodic screening tests for possible
complications and multidisciplinary approach for children
with SCD. The determination of reliable early predictors of
SCD severity would help to balance the risks between inter-
ventions and disease itself, providing an improvement in the
comprehensive care of these patients. Leucocytosis and
dactylitis in the early infancy can be predictors of SCD
severity, while the presence of a-thalassemia can be protec-
tive. More studies are needed to predict the individual risk
of chronic complications of SCD, to optimize the follow-up
and treatment of the disease.
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